Riccardo Perfetti - May 11, 2021 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role
Chief Medical Officer
Signature
/s/ Shoshana Shendelman, Attorney-in-Fact
Stock symbol
APLT
Transactions as of
May 11, 2021
Transactions value $
-$3,166
Form type
4
Date filed
5/13/2021, 07:41 PM
Next filing
May 26, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLT Common Stock Options Exercise $288 +200 $1.44 200 May 11, 2021 Direct F1
transaction APLT Common Stock Sale -$3.45K -200 -100% $17.27* 0 May 11, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -200 -0.12% $0.00 174K May 11, 2021 Common Stock 200 $1.44 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.1700 to $17.2700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.